LRRC19 and breast cancer: Further survival analysis in four human common cancers (including breast cancer, lung cancer, gastric cancer, and ovarian cancer) inferred that lower LRRC19 expression significantly correlates with poorer progression (including OS, RFS, PPS, DMPS, FP, or PFS) in patients, suggesting the potential value of lower LRRC19 expression on prognostic prediction.